126 related articles for article (PubMed ID: 29619416)
21. Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
Jensen CM; Holle LM
Pharmacotherapy; 2016 May; 36(5):562-74. PubMed ID: 27027412
[TBL] [Abstract][Full Text] [Related]
22. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions.
Holder KA; Stapleton SN; Gallant ME; Russell RS; Grant MD
J Immunol; 2013 Sep; 191(6):3308-18. PubMed ID: 23960237
[TBL] [Abstract][Full Text] [Related]
24. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
25. Interferon-α-Enhanced CD100/Plexin-B1/B2 Interactions Promote Natural Killer Cell Functions in Patients with Chronic Hepatitis C Virus Infection.
He Y; Guo Y; Fan C; Lei Y; Zhou Y; Zhang M; Ye C; Ji G; Ma L; Lian J; Moorman JP; Yao ZQ; Wang J; Hao C; Zhang Y; Jia Z
Front Immunol; 2017; 8():1435. PubMed ID: 29163508
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3.
Golden-Mason L; Waasdorp Hurtado CE; Cheng L; Rosen HR
Clin Immunol; 2015 May; 158(1):114-25. PubMed ID: 25797693
[TBL] [Abstract][Full Text] [Related]
27. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Curry MP; Tapper EB; Bacon B; Dieterich D; Flamm SL; Guest L; Kowdley KV; Lee Y; Milligan S; Tsai N; Younossi Z; Afdhal NH
Aliment Pharmacol Ther; 2017 Sep; 46(5):540-548. PubMed ID: 28691377
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
30. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
31. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
32. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
[TBL] [Abstract][Full Text] [Related]
33. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
34. HIV mono-infection is associated with an impaired anti-hepatitis C virus activity of natural killer cells.
Goeser F; Glässner A; Kokordelis P; Wolter F; Lutz P; Kaczmarek DJ; Schwarze-Zander C; Boesecke C; Strassburg CP; Rockstroh JK; Spengler U; Krämer B; Nattermann J
AIDS; 2016 Jan; 30(3):355-63. PubMed ID: 26558728
[TBL] [Abstract][Full Text] [Related]
35. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
36. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
[TBL] [Abstract][Full Text] [Related]
37. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.
Maghrabi HME; Elmowafy AY; Refaie AF; Elbasiony MA; Shiha GE; Rostaing L; Bakr MA
Int Urol Nephrol; 2019 Dec; 51(12):2295-2304. PubMed ID: 31531807
[TBL] [Abstract][Full Text] [Related]
39. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
40. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.
Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV
Hepatology; 2016 Dec; 64(6):1911-1921. PubMed ID: 27639183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
